Why Health Innovation Fails at Scale — and What National Execution Actually Requires — by Anjo De Heus

 

Over the past decade, global health has not suffered from a lack of innovation.

On the contrary, we have seen an explosion of diagnostics, digital platforms, AI-driven tools, and breakthrough technologies aimed at improving detection, prevention, and care. Funding rounds are announced, pilots are launched, innovation hubs are opened, and conferences celebrate progress.

Yet outcomes tell a different story.

Across large parts of Africa and the GCC, preventable diseases are still detected too late, diagnostic access remains uneven, and national health systems struggle to absorb and sustain innovation at scale.

This is not a technology problem.

It is an execution problem.

The Illusion of Progress

Modern health innovation has become very good at creating signals of momentum.

Pilots demonstrate intent.
Innovation labs show ambition.
Proof-of-concepts validate ideas.

But too often, these signals are mistaken for systems.

A pilot that works in one hospital does not automatically translate into national deployment. A grant-funded project does not become infrastructure. A successful demo does not resolve manufacturing, governance, or workforce constraints.

Progress is announced early. Execution is postponed indefinitely.

The result is what many quietly recognize but rarely say aloud:
we have learned how to start well, but not how to finish.

Why Technology Is Rarely the Limiting Factor

When initiatives fail to scale, technology is often blamed first.

But in practice, most of the technologies entering pilots today already work:

• Diagnostics can detect disease accurately
• Digital platforms can manage data securely
• AI models can support clinical decision-making

What fails is not performance — it is absorption.

Health systems struggle to absorb innovation when:

• There is no localization or manufacturing pathway
• Regulatory integration is treated as an afterthought
• Workforce training is externalized or temporary
• Ownership is fragmented across agencies and partners

Technology can be imported quickly.
Capability cannot.

The Execution Gap Nobody Owns

Perhaps the most uncomfortable truth in global health is this:
everyone participates in innovation — but no one truly owns scale.

• Governments fund programs, often tied to political or budget cycles
• Development finance institutions fund projects, not long-term operating systems
• Innovators optimize for pilots because pilots are fundable and fast

Each actor behaves rationally within their own incentives.

Collectively, however, the system produces fragmentation:

• Scale is always “next phase”
• Manufacturing is “future localization”
• Governance is “to be aligned later”

The execution gap sits in between institutions, unowned and unresolved.

What National Execution Actually Requires

National-scale health execution is not a phase that follows innovation.
It is a discipline that must be designed upfront.

From experience, durable execution rests on several principles:

1. Execution architecture must precede deployment
National systems require clear operating models, governance structures, and accountability before technology is rolled out.

2. Localization is not optional
Manufacturing, assembly, or at minimum technical transfer must be embedded early to reduce dependency and ensure continuity.

3. Public–private partnerships must align beyond funding
PPPs only work when incentives extend past grants and contracts, toward shared ownership of long-term outcomes.

4. Workforce development is part of the system, not a support function
Skills, training, and institutional memory determine whether systems survive leadership changes and funding cycles.

Scale is not achieved by adding more pilots.
It is achieved by building systems that do not need pilots to survive.

Sovereignty Is Operational, Not Political

Health sovereignty is often discussed as a political aspiration.

In practice, it is far more pragmatic.

Sovereignty means:

• Domestic capability to diagnose and respond
• Local control over critical infrastructure and data
• Reduced reliance on emergency imports and ad hoc programs

It is not about isolation.
It is about resilience.

Countries that treat execution as infrastructure — not as projects — are better prepared, more adaptive, and ultimately more attractive partners for innovation and investment alike.

A Different Measure of Progress

The next phase of global health will not be led by those who innovate fastest, raise the most capital, or announce the most pilots.

It will be led by those who can:

• Translate innovation into national capacity
• Align technology with governance and ownership
• Build systems that endure beyond funding cycles

Innovation creates possibility.
Execution creates reality.

Until we treat execution as a system — not a milestone — the gap between promise and impact will remain.